Kodiak Sciences (NASDAQ:KOD) Price Target Raised to $4.00

Kodiak Sciences (NASDAQ:KOD) had its price objective lifted by Barclays from $3.00 to $4.00 in a research report released on Friday morning,Benzinga reports. They currently have an underweight rating on the stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $3.00 price target on shares of Kodiak Sciences in a research report on Friday.

Kodiak Sciences Stock Up 2.4 %

KOD stock opened at $5.66 on Friday. The business has a 50 day moving average price of $3.42 and a 200 day moving average price of $3.06. The stock has a market cap of $297.83 million, a price-to-earnings ratio of -1.55 and a beta of 2.26. Kodiak Sciences has a fifty-two week low of $2.18 and a fifty-two week high of $7.77.

Institutional Trading of Kodiak Sciences

Several hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC grew its holdings in Kodiak Sciences by 14.1% during the second quarter. Acadian Asset Management LLC now owns 1,965,449 shares of the company’s stock worth $4,614,000 after acquiring an additional 242,559 shares during the period. Vanguard Group Inc. grew its stake in shares of Kodiak Sciences by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 1,654,448 shares of the company’s stock worth $8,702,000 after purchasing an additional 10,978 shares during the period. State Street Corp increased its holdings in shares of Kodiak Sciences by 1.8% in the 3rd quarter. State Street Corp now owns 816,634 shares of the company’s stock valued at $2,131,000 after purchasing an additional 14,711 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Kodiak Sciences by 1.7% during the 3rd quarter. Geode Capital Management LLC now owns 768,740 shares of the company’s stock valued at $2,007,000 after acquiring an additional 12,783 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Kodiak Sciences by 21.9% during the 2nd quarter. Renaissance Technologies LLC now owns 708,800 shares of the company’s stock worth $1,666,000 after acquiring an additional 127,400 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.